- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NEJM Study Could Influence Medicare Coverage of CT Screening in Lung Cancer
The study results from the National Lung Screening Trial found cost-effectiveness and value of screening long-term smokers when screened by trained professionals.
Lung cancer screening with CT scans can be cost-effective while saving lives, a new study suggests.
But, there are two caveats to that finding -- the procedure has to be performed by skilled professionals and the screening must be done on a very specific set of long-time smokers, the researchers noted.
Results from the National Lung Screening Trial (NLST) showed four years ago that annual CT scans can reduce lung cancer deaths by 20 percent in older, long-time smokers.
The new study, which uses data gathered during that national trial, concludes that screening for lung cancer would cost $81,000 for each year of quality life gained -- lower than the generally accepted $100,000-per-year threshold for cost effectiveness.
Link to the complete report: http://1.usa.gov/13Rsylv
Source: MedlinePlus
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
